215 related articles for article (PubMed ID: 16882080)
1. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
Kobayashi M; Kuramoto H; Ota J; Fujimoto N
Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
[TBL] [Abstract][Full Text] [Related]
2. [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].
Kobayashi S; Tsukamoto T; Tohsaka A; Tohma T
Hinyokika Kiyo; 2008 Jun; 54(6):423-6. PubMed ID: 18634439
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
4. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
[TBL] [Abstract][Full Text] [Related]
5. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of hormone-refractory prostate cancer with estramustine phosphate].
Morote J; López-Pacios MA; Ahmad A; Vila J; de Torres JA
Actas Urol Esp; 1991; 15(5):421-4. PubMed ID: 1725472
[TBL] [Abstract][Full Text] [Related]
7. [Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate].
Morote J; Lorente JA; Vallejo C; Encabo G; López-Pacios MA; De Torres JA; Soler Rosello A
Actas Urol Esp; 1994 Jun; 18(6):656-9. PubMed ID: 7524278
[TBL] [Abstract][Full Text] [Related]
8. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate.
Suzuki M; Mamun MR; Hara K; Ozeki T; Yamada Y; Kadowaki T; Honda H; Yanagihara Y; Ito YM; Kameyama S; Ohta N; Hosoi T; Arai T; Sawabe M; Takeuchi T; Takahashi S; Kitamura T
Eur Urol; 2005 Nov; 48(5):752-9. PubMed ID: 16126332
[TBL] [Abstract][Full Text] [Related]
9. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
11. [Clinical course of hormone refractory cancer of the prostate].
Morote J; Vila J; López-Pacios MA; De Torres JA; Soler-Roselló A
Actas Urol Esp; 1992 Oct; 16(9):722-5. PubMed ID: 1283286
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Yoneyama T; Hashimoto Y; Kamimura N
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):397-401. PubMed ID: 22890389
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
15. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
Ward JF
Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
[No Abstract] [Full Text] [Related]
16. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
18. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
19. Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer.
Pintér O; Molnár J; Tóth C; Szabó Z; Lipták J; Fél P; Papp G; Hollman E; Hazay L; Streit B; Kisbenedek L; Fehér M; Kocsis I; Pajor L
In Vivo; 2005; 19(4):787-92. PubMed ID: 15999550
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].
Awakura Y; Yamamoto M; Fukuzawa S; Itoh N; Nonomura M; Fukuyama T
Hinyokika Kiyo; 2000 Jul; 46(7):449-52. PubMed ID: 10965448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
